Результаты поиска

STAT3 pathway in cancers: Past, present, and future.

Signal transducer and activator of transcription 3 (STAT3), a member of the STAT family, discovered in the cytoplasm of almost all types of mammalian cells, plays a significant role in biological functions. The duration of STAT3 activation in normal tissues is a transient event and is strictly regulated. However, in cancer tissues, STAT3 is activated in an aberrant manner and is induced by certain cytokines. The continuous activation of STAT3 regulates the expression of downstream proteins associated with the formation, progression, and metastasis of cancers. Thus, elucidating the mechanisms o…

MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.

Among childhood cancers, neuroblastoma is the most diffuse solid tumor and the deadliest in children. While to date, the pathology has become progressively manageable with a significant increase in 5-year survival for its less aggressive form, high-risk neuroblastoma (HR-NB) remains a major issue with poor outcome and little survivability of patients. The staging system has also been improved to better fit patient needs and to administer therapies in a more focused manner in consideration of pathology features. New and improved therapies have been developed; nevertheless, low efficacy and high

Proceedings of Reanimation 2023, the French Intensive Care Society International Congress.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications.

The tumor microenvironment (TME) has been extensively investigated; however, it is complex and remains unclear, especially in elderly patients. Senescence is a cellular response to a variety of stress signals, which is characterized by stable arrest of the cell cycle and major changes in cell morphology and physiology. To the best of our knowledge, senescence leads to consistent arrest of tumor cells and remodeling of the tumor-immune microenvironment (TIME) by activating a set of pleiotropic cytokines, chemokines, growth factors, and proteinases, which constitute the senescence-associated sec

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

BACKGROUND: Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs). GBD 2023 aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex. This study enables comparis

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management.

Radiopharmaceuticals (RPhs) represent a breakthrough in nuclear medicine due to their ability to provide precise diagnosis and targeted therapy for cancer by incorporating radioactive isotopes into carrier molecules. This review systematically discusses the recent advances in the development of RPhs, focusing on state-of-the-art probe design strategies and click chemistry applications that accelerate RPh syntheses and improve targeting efficiency. The manuscript synthesizes literature from multiple databases spanning January 2014 to April 2025, encompassing diagnostic modalities including posi

Targeting signaling pathways in lymphoma: From molecular mechanisms to clinical breakthroughs.

AbstractThe treatment paradigm for lymphoma, a highly heterogeneous group of hematologic malignancies, has been revolutionized by the development of therapies targeting oncogenic signaling pathways. This shift from conventional chemotherapy to precision medicine is driven by a deep molecular understanding of the pathways that govern lymphoma cell survival and proliferation. This review comprehensively surveys the landscape of these targeted therapies, from fundamental molecular mechanisms to clinical breakthroughs. We first dissect the molecular architecture of key oncogenic drivers, covering …

Advances and Prospects of Prolamine Corn Protein Zein as Promising Multifunctional Drug Delivery System for Cancer Treatment.

Zein is a type of prolamine protein that is derived from corn, and it has been recognized by the US FDA as one of the safest biological materials available. Zein possesses valuable characteristics that have made it a popular choice for the preparation of drug carriers, which can be administered through various routes to improve the therapeutic effect of antitumor drugs. Additionally, zein contains free hydroxyl and amino groups that offer numerous modification sites, enabling it to be hybridized with other materials to create functionalized drug delivery systems. However, despite its potential

Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.

Cancer is the second leading cause of death worldwide after cardiovascular diseases. Harnessing the power of immune cells is a promising str … e, and status of bsAb-based ICEs in clinical development and their approval by the US FDA for human malignancy treatment, but also on summarizing the currently known and emerging therapeutic targets in cancer. This review provides insights into practical considerations for developing next-generation ICEs.

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30-40% of patients experience refractory or relapse. For several decades, the standard treatment strategy for fit relapsed/refractory (R/R) DLBCL patients has been high-dose chemotherapy followed by autologous hematopoietic stem cell transplant (auto-SCT). However, the patients who failed in salvage treatment or those ineligible for subsequent auto-SCT have dismal outcomes. Several immune-based therapies have been developed, including monoclonal antibodies, antibody-drug conjugates, b

Immunomodulatory Nanosystems.

Immunotherapy has emerged as an effective strategy for the prevention and treatment of a variety of diseases, including cancer, infectious diseases, inflammatory diseases, and autoimmune diseases. Immunomodulatory nanosystems can readily improve the therapeutic effects and simultaneously overcome many obstacles facing the treatment method, such as inadequate immune stimulation, off-target side effects, and bioactivity loss of immune agents during circulation. In recent years, researchers have continuously developed nanomaterials with new structures, properties, and functions. This Review provi

Совпадение в полном тексте источника
… . | GlaxoSmithKline | Malaria | Phase III | London School of Hygiene and Tropical Medicine | NCT03143218 | – | Burkina Faso, Mali | 5920 | 2017–2020 | – | | | | Plasmodium falciparum malaria | Phase I/II | University of Oxford | NCT01883609 | ChAd63 ME‐TRAP, MVA ME‐TRAP | U.K. | 48 | 2013–2014 | …

Esid 2014 oral presentations.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies.

The role of immunotherapy in oncohematology is well established. Monoclonal antibodies have undergone substantial development in recent years, targeting a wide range of molecules (including surface antigens, immune checkpoints, and cytokines) and have demonstrated clinical utility across various hematologic malignancies, including leukemias, lymphomas, and myelomas. The emergence of advanced therapy medicinal products (ATMPs), particularly chimeric antigen receptor (CAR) T cells, has provided an additional and promising therapeutic option. This rapidly evolving field continues to expand therap…

Screening the Active Phytochemicals From Eclipta prostrata and Unraveling Their Molecular Insight Into Human Malignancies.

Current drugs against multiple human malignancies are limited, and developing new treatment strategies is improbable within a short time. So, considering the current situation, phytochemicals could be a viable option for developing chemotherapeutic agents for managing numerous types of malignancies. Therefore, we aimed to locate all phytochemicals of Eclipta prostrata and unravel their chemotherapeutic mechanisms and strategies individually. We defined 25 active compounds based on their anticancer activities after filtering through IMPPAT and literature search, and these compounds have chemoth…

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.

Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, Bruton tyrosine kinase, FLT3, BCL-2, IDH1, IDH2, are biomarker-driven chemotherapy-free agents approved for several major hematological malignancies. LOXO-305, asciminib, "off-the-shelf" universal CAR-T cells and BCMA-directed immunotherapeutics as well as data from clinical trials on many novel agents and regimens were updated at the 2020 American Society of Hematology (ASH) Annual Meeti…

Резюме ESPR 2013Европейское общество педиатрической радиологии 50th Ежегодное совещание и 36th Курсы для аспирантов. Июнь 3–7 2013. Будапешт, Венгрия.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Tumor microenvironment signaling and therapeutics in cancer progression.

Tumor development and metastasis are facilitated by the complex interactions between cancer cells and their microenvironment, which comprises stromal cells and extracellular matrix (ECM) components, among other factors. Stromal cells can adopt new phenotypes to promote tumor cell invasion. A deep understanding of the signaling pathways involved in cell-to-cell and cell-to-ECM interactions is needed to design effective intervention strategies that might interrupt these interactions. In this review, we describe the tumor microenvironment (TME) components and associated therapeutics. We discuss t

49th ESCP virtual symposium on clinical pharmacy 19.10.2021-21.10.2021 Clinical pharmacy, working collaboratively in mental health care.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Экстракорпоральное обнаружение биомаркеров и патогенов в слюне: всеобъемлющий, панорамный обзор.

Человеческая слюна представляет собой разнородную жидкость с сложным составом, которая содержит антитела, белки и вирусы, что делает ее применимой в клинической диагностике. Анализ проб слюны имеет несколько преимуществ по сравнению с другими биофильтрами, включая неинвазивную и простую процедуру сбора для эксторального обнаружения. Диагностика биомаркеров или патогенов в слюне может осуществляться различными методами: масс-спектрометрией, ПЦР, ЭЛИСА, электрохимическими и оптическими методами, такими, как флуоресцентная, SPR и SERS. Раннее обнаружение раковых и других биомаркеров заболеваний,

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

BACKGROUND: How long one lives, how many years of life are spent in good and poor health, and how the population's state of health and leading causes of disability change over time all have implications for policy, planning, and provision of services. We comparatively assessed the patterns and trends of healthy life expectancy (HALE), which quantifies the number of years of life expected to be lived in good health, and the complementary measure of disability-adjusted life-years (DALYs), a composite measure of disease burden capturing both premature mortality and prevalence and severity of ill

Совпадение в полном тексте источника
… –54·5) | 62·6 (60·3–64·9) | 45·5 (43·3–47·6) | 57·4 (55·1–59·7) | 44·6 (41·7–47·4) | 53·9 (50·8–56·8) | 39·8 (37·5–42·2) | 50·2 (47·4–52·8) Liberia | 51·3 (49·5–53·1) | 65·1 (63·1–67·4) | 46·8 (45·3–48·4) | 63·7 (61·5–65·8) | 43·4 (40·6–45·8) | 54·7 (51·3–57·8) | 39·9 (37·6–42·3) | 54·0 (50·9–57·3) Mali … Guinea-Bissau | 11·3 (10·4–12·5) | 13·0 (11·8–14·5) | 9·6 (8·9–10·5) | 11·4 (10·6–12·1) | 8·2 (7·1–9·3) | 9·5 (8·2–10·7) | 7·0 (6·1–7·9) | 8·4 (7·4–9·3) Liberia | 12·6 (11·7–13·5) | 14·1 (12·8–15·5) | 12·5 (11·7–13·3) | 13·7 (12·6–14·6) | 8·7 (7·6–9·8) | 10·0 (8·6–11·3) | 8·9 (7·7–10) | 9·8 (8·6–11·1) Mali …